Uracil
CAS 66-22-8
Uracil (CAS 66-22-8) is a Phase 3 pharmaceutical compound with 6 bioactivity targets and 7 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 449890.82862068963 nM | 58 | - |
| - | IC50 | 597990.524 nM | 4 | - |
| - | AC50 | 42239.55 nM | 2 | - |
| - | EC50 | 29.5 ug.mL-1 | 2 | - |
| - | Potency | 19321.800000000003 nM | 2 | - |
| - | Ki | 35000 nM | 1 | - |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Uracil used for in pharmaceutical contexts?
Uracil (CAS 66-22-8) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Uracil?
Uracil has 7 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Cellulitis, Cystitis noninfective, Hip surgery, Mass, Miliaria. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Uracil also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Uracil with EU status "permitted".
What clinical phase is Uracil in?
Uracil is rendered with ChEMBL max phase 3.